Please provide your email address to receive an email when new articles are posted on . Because of limited population-based data on SFN, the researchers aimed to investigate SFN incidence, prevalence, ...

Over the past two decades, there has been a significant increase in the number of adults in the United States with small fiber neuropathy (SFN), but in many cases, no cause can be determined. The ...

Please provide your email address to receive an email when new articles are posted on . Small fiber neuropathy, a pain-inducing condition that resembles and overlaps with fibromyalgia, may be ...

ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

A significant proportion of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and dysautonomia may have potentially treatable underlying autoimmune-associated small-fiber ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

The number of people experiencing numbness, tingling and pain in their feet with no known cause has been increasing over the last two decades, according at a new study. Called small fiber neuropathy, ...

A: The brain sends/receives electric signals that control/sense different muscles and body functions/sensory signals. These electrical signals travel either directly from the brain to the signal ...

Prolonged, often disabling, small-fiber neuropathy in long COVID may be caused by a defective immune response, a small longitudinal study suggested. Peripheral neuropathy was identified in 59% of 17 ...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast ...